RBC Capital maintains Sylvamo at Sector Perform, raises price target to $37 from $35

RBC Capital kept its Sector Perform rating on Sylvamo but raised its price target to $37 from $35, suggesting a 6.0% downside from the last close. Recent analyst targets for the company range from $35 to $42.

Original reporting
Published Nov 9, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RBC Capital maintains Sylvamo at Sector Perform, raises price target to $37 from $35 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The price target increase reflects a modest bullish view but lacks a concrete catalyst.

02

Market read

Analyst note provides a small informational edge; limited trading impact.

03

What to watch

No new earnings or contract news; price target change alone may not move the stock significantly.

Relevance 5/10Novelty 4/10Timing: today

Background

Sylvamo is a specialty chemicals company; analyst coverage is limited.

Market effects

May lift sentiment in specialty chemicals sector.

Limited to US market participants.

Minimal global impact.

Counterpoint

Target raise could be premature if underlying fundamentals remain weak.

Key entities

  • RBC Capital

    Raised Sylvamo price target to $37.

Related articles

$SLVMMedAI 8/10

Sylvamo Q3 Earnings Call Highlights

Sylvamo (SLVM) reported Q3 adjusted EBITDA improved by $25M due to price increases, with flat volume. Input costs rose by $6M, but the company expects to mitigate further increases. Projects at Eastover and Sumter mills are on track, with expected capacity expansions. The company declined to update free cash flow targets post-Europe transaction but reaffirmed capital allocation priorities, including dividends and share repurchases.

$SLVMMed

Sylvamo Corp (SLVM) (Q3 2026) Earnings Call Highlights: Adjusted EBITDA Nearly Doubles

Sylvamo Corp (SLVM) reported Q3 2026 adjusted EBITDA of $128M, nearly doubling from Q2. CEO John Sims and CFO John Devlin discussed 2027 outlook, noting uncertainties but expecting $25M of non-repeat items. They also addressed the Europe deal, Sumter sheeter expansion, and cost mitigation strategies. The company's shareholder rights plan will expire on Nov 9, 2026. North America shipments are expected to be flat in 2027, with industry decline of about 2% in 2026.

Med

Sylvamo Corporation Q3 2026 Earnings Call Summary

Sylvamo Corporation reported Q3 2026 earnings, highlighting a strategic pivot to North and Latin America, operational improvements, and planned divestiture of European business by Q1 2027. The company expects $6M higher input costs in Q4 2026 and projects flat North American volume in 2027. Management deferred new free cash flow targets until the European sale is finalized, prioritizing balance sheet strength and high-return projects.

$SLVMMed

Sylvamo (SLVM) Q3 2026 Earnings Call Transcript

Sylvamo (SLVM) reported Q3 2026 net sales of $645 million, adjusted EBITDA of $128 million, and adjusted earnings of $1.33 per share. The company agreed to divest European operations, retaining a 20% interest, and plans capacity expansions in the U.S. Management highlighted price increases and operational improvements but noted ongoing cost pressures. The board did not renew the shareholder rights plan. (350 characters)

$SLVMMed

Sylvamo Reports Third Quarter 2026 Earnings

Sylvamo (SLVM) reported Q3 2026 earnings, with net sales of $645M from continuing operations and net income of $85M ($2.13 per share). The company announced a potential sale of its Europe business to Midas Atlantic Partners and The Najafi Companies. Sylvamo declared a $0.45 per share dividend and is investing in strategic projects at its Eastover mill. The company expects to focus on Latin America and North America post-transaction.